Cardiol Therapeutics faced a notable decline in its stock price, reflecting investor concerns.
Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a drop of 3.37% in its stock price during yesterday's trading session, closing at CA$2.87. This decline comes amidst a lack of significant company news that could have influenced investor sentiment positively.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$346.96M
52W high
$3.15
52W low
$1.23
1W change
+9.96%
Beta
0.47
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 109.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+109.1% Upside
Current Price
C$2.87
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
69.7%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$3.43
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.05 | C$2.39 โ C$3.87 |
| 60 trading days | C$3.23 | C$2.30 โ C$4.54 |
| 90 trading days | C$3.43 | C$2.26 โ C$5.20 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious given the recent performance of Cardiol Therapeutics, especially in the absence of fresh developments to bolster confidence.
3.37% Decline in Stock Price
Cardiol Therapeutics' stock fell by 3.37%, reflecting investor apprehension in a volatile market.
Bull case
If Cardiol Therapeutics can successfully advance its clinical trials and secure additional funding, it may regain investor confidence and drive its stock price higher. Positive results could signal a turnaround, attracting more investors and improving market sentiment.
Bear case
Continued uncertainty in the biotech sector and the absence of positive news could lead to further declines in Cardiol Therapeutics' stock, as investors weigh the risks of its ongoing projects. Without fresh updates, the stock may struggle to recover, leaving investors wary.
Market Reaction
Advertisement
The decline in Cardiol Therapeutics' stock price reflects broader market trends and investor sentiment. With a market cap of approximately CA$346 million, the company is under scrutiny as it navigates its clinical trials and funding efforts. The absence of significant news may have exacerbated the drop, leading investors to reassess their positions.
Future Outlook
Looking ahead, Cardiol Therapeutics has the potential to recover if it can deliver positive results from its ongoing trials, particularly the Phase III MAVERIC trial for recurrent pericarditis. However, the current market conditions and investor skepticism may pose challenges for the company as it seeks to regain momentum. For more insights on CRDL.TO, check out our detailed analysis here.
Investor Considerations
Investors should weigh the risks associated with Cardiol Therapeutics' current trajectory. With no recent announcements to bolster confidence, the stock's performance may continue to reflect broader market uncertainties. For those looking to invest, it may be prudent to monitor developments closely and consider the implications of the company's ongoing projects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
